DexCom, Inc. $DXCM Shares Sold by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 70.5% during the first quarter, HoldingsChannel reports. The institutional investor owned 19,899 shares of the medical device company’s stock after selling 47,559 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in DexCom were worth $1,250,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in the company. Gradient Investments LLC raised its position in DexCom by 13.8% during the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock worth $22,035,000 after buying an additional 40,343 shares during the last quarter. Nordea Investment Management AB lifted its stake in shares of DexCom by 118.6% in the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after acquiring an additional 137,986 shares during the period. Banco Santander S.A. boosted its holdings in shares of DexCom by 28.9% in the third quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock valued at $16,843,000 after acquiring an additional 56,062 shares in the last quarter. Banque Pictet & Cie SA increased its stake in shares of DexCom by 58.2% during the fourth quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock worth $7,289,000 after acquiring an additional 40,411 shares during the period. Finally, Holocene Advisors LP acquired a new position in shares of DexCom during the third quarter worth about $163,964,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DXCM. UBS Group set a $95.00 price objective on shares of DexCom in a research report on Wednesday, June 10th. Benchmark reissued a “buy” rating on shares of DexCom in a research note on Tuesday. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a report on Monday, June 1st. Mizuho set a $85.00 price target on DexCom and gave the company an “outperform” rating in a research note on Tuesday, June 9th. Finally, BTIG Research reaffirmed a “buy” rating and set a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.88.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the transaction, the executive vice president owned 106,353 shares in the company, valued at $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the transaction, the director directly owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 46,694 shares of company stock valued at $3,343,977 in the last three months. 0.28% of the stock is owned by insiders.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $69.73 on Thursday. The firm has a market capitalization of $26.91 billion, a price-to-earnings ratio of 29.80, a price-to-earnings-growth ratio of 1.08 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64. The business’s 50 day simple moving average is $67.36 and its 200-day simple moving average is $68.04. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the business posted $0.32 EPS. As a group, equities analysts forecast that DexCom, Inc. will post 2.58 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.